Navigation Links
Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting
Date:6/1/2009

tabine (GEM) in Patients (pts) with Advanced Cancer." The results, which were previously announced in March 2009, demonstrated that the combination of REOLYSIN and gemcitabine was well tolerated, and resulted in disease control for a majority of the patients. Of the ten patients evaluable for response, two patients (breast and nasopharyngeal) had partial responses (PRs) and/or clinical responses and five patients had SD for 4-8 cycles, for a total disease control rate (CR (Complete Response)+PR+SD) of 70%.

Dr. Sanjay Goel and colleagues delivered a poster entitled "Dose Escalation and Pharmacodynamic Study of Intravenous Administration of REOLYSIN, a Live Replication Competent RNA Virus in Patients with Advanced Solid Tumors." The results, which were previously announced in June 2007, demonstrated that REOLYSIN was well tolerated. Of 18 patients treated in the trial, eight demonstrated SD or better as measured by Response Evaluation Criteria in Solid Tumors (RECIST) including a patient with progressive breast cancer who experienced a PR (34% shrinkage in tumor volume).

All three posters will be available today on the Oncolytics website at www.oncolyticsbiotech.com

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit www.oncolyticsbiotech.com

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech(R) Inc.s Research Collaborators to Present Data on REOLYSIN(R) Clinical Trials at ASCO Conference
2. Oncolytics(R) Biotech Inc. Completes Patient Enrolment in U.S. Phase 2 Sarcoma Study
3. Oncolytics Biotech(R) Inc. Announces 2009 First Quarter Results
4. Oncolytics Biotech(R) Inc. Announces Details of 2009 Annual Shareholder Meeting
5. Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioFinance 2009
6. Oncolytics Biotech(R) Inc. Announces Positive Results of U.K. Phase II REOLYSIN(R) and Radiation Combination Clinical Trial
7. Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial
8. Oncolytics Biotech(R) Inc. Collaborators Present Reovirus Research at Replicating Oncolytic Virus Meeting
9. Oncolytics Biotech(R) Inc. Collaborators Present Positive Head and Neck Results in Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Trial
10. Oncolytics Biotech(R) Inc. Collaborators Update Combination REOLYSIN(R) and Docetaxel Trial Results at Replicating Oncolytic Virus Meeting
11. Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at AACR Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar will ... and clinical safety assessment in biosimilars. , Regulatory frameworks ... biosimilar drug development, however the complex nature of biopharmaceuticals ... safety and efficacy extremely challenging. Based on the specific ...
(Date:1/15/2014)... TX (PRWEB) January 15, 2014 More ... disease, and about 1 in 3 seniors will die ... source ). These jaw-dropping figures have shocked many Americans ... and, hopefully, help prevent these tragic age-related cognitive disorders. ...
(Date:1/15/2014)... Rochester, NY (PRWEB) January 15, 2014 The ... cause a major disease. One of these latent viruses is ... is rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic ... the theory, a study found that RA patients have high ...
(Date:1/15/2014)... 2013 was a banner year of ... They saw continued independent research led by the team ... a $1 million grant from the Susanne Marcus Collins ... a peer reviewed journal, Amy Grant highlighted Brainwave Optimization® ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3
... Inc. (Nasdaq: NVAX ) announced today that it has ... the National Institute of Allergy and Infectious Diseases (NIAID) of ... the NIAID is to support a segment of the Company,s ... vaccine. RSV is the most commonly identified cause of ...
... ... including the life sciences, oil and gas, and chemical industries, Smith provides a successful ... that consistently exceed revenue targets. , ... Chicago, IL (PRWEB) October 13, 2009 -- ClearTrial ( www.cleartrial.com ), ...
... 13 Amsterdam Molecular,Therapeutics (Euronext: AMT), a leader in ... European Medicines Agency has granted Orphan Drug,Designation to AMT,s ... dystrophy. , Orphan Drug Designation ... market exclusivity in Europe following marketing approval for,AMT-080 if ...
Cached Biology Technology:Novavax Awarded NIH Grant for Respiratory Syncytial Virus (RSV) Vaccine Program 2Novavax Awarded NIH Grant for Respiratory Syncytial Virus (RSV) Vaccine Program 3ClearTrial Names Proven Enterprise Software and Life Sciences Sales Leader Craig Smith as Vice President of Sales 2ClearTrial Names Proven Enterprise Software and Life Sciences Sales Leader Craig Smith as Vice President of Sales 3AMT Receives EMEA Orphan Drug Designation for Duchenne Muscular Dystrophy 2AMT Receives EMEA Orphan Drug Designation for Duchenne Muscular Dystrophy 3
(Date:4/17/2014)... in bone marrow need to produce hydrogen sulfide in ... to a new study from the Center for Craniofacial ... of USC. , Professor Songtao Shi, principal investigator on ... by the cells governs the flow of calcium ions. ... that results in osteogenesis, or the creation of new ...
(Date:4/17/2014)... Several parasites and pathogens that devastate honeybees in Europe, ... Africa, but do not appear to be impacting native ... team of researchers., The invasive pests include including ... East African honeybees appear to be resilient to these ... used to control pests in Europe, Asia and the ...
(Date:4/17/2014)... Yokahama IPCC meeting painted a stark warning on the ... has a greenhouse effect 32 times that of carbon ... that humic substances act as fully regenerable electron acceptors ... held in wetlands instead of being released to the ... is disrupted it may enter into a vicious cycle ...
Breaking Biology News(10 mins):East African honeybees are safe from invasive pests… for now 2East African honeybees are safe from invasive pests… for now 3Methane climate change risk suggested by proof of redox cycling of humic substances 2
... Boulder, Colo., USA New Geology postings extend ... years; determine erosion rates for exposure of today,s ... pulses; call mudstones "so complicated as to almost ... the oldest rocks on Earth; postulate that biomarkers ...
... rate of molecular evolution between humans and chimps with that of ... at a steady pace in all creatures or if subtle changes ... occur more rapidly in some groups than in others. ... the Royal Society B . The team chose its study ...
... , Jan. 7, 2014 /PRNewswire-iReach/ -- As part of the ... announced the acquisition of MDSL International - a specialist clinical ... Data Management and Statistical services. The financial details of the ... branch of CROS NT, sees the acquisition as an important ...
Cached Biology News:Geological Society of America's top journal, Geology, begins 2014 with 10 new articles 2Geological Society of America's top journal, Geology, begins 2014 with 10 new articles 3Geological Society of America's top journal, Geology, begins 2014 with 10 new articles 4Geological Society of America's top journal, Geology, begins 2014 with 10 new articles 5Geological Society of America's top journal, Geology, begins 2014 with 10 new articles 6Geological Society of America's top journal, Geology, begins 2014 with 10 new articles 7Geological Society of America's top journal, Geology, begins 2014 with 10 new articles 8Geological Society of America's top journal, Geology, begins 2014 with 10 new articles 9Of lice and men (and chimps): Study tracks pace of molecular evolution 2Of lice and men (and chimps): Study tracks pace of molecular evolution 3CROS NT Ltd Announces Acquisition of MDSL International Ltd. 2CROS NT Ltd Announces Acquisition of MDSL International Ltd. 3
B.D. Hames and D.M. Glover (1996) • This issue covers T-Cell antigen receptor genes; T-Lymphocyte signal transduction; B-Cell activation antibody engineering and the complement system and other ...
Request Info...
...
RABBIT ANTI PORCINE CARBOXYPEPTIDASE B...
Biology Products: